Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
The DOI matches its Crossref record; 201 of the 202 references it cites were found in a registry or an index.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is predicted to be the second most common cause of death within the next 10 years. The prognosis for this disease is poor despite diagnostic progress and new chemotherapeutic regimens. The oncogenic KRAS mutation is the major event in pancreatic cancer; it confers permanent activation of the KRAS protein, which acts as a molecular switch to activate various intracellular signalling pathways and transcription factors inducing cell proliferation, migration, transformation and survival. Several laboratory methods have been developed to detect KRAS mutations in biological samples, including digital droplet PCR (which displays high sensitivity). Clinical studies have revealed that a KRAS mutation assay in fine-needle aspiration material combined with cytopathology increases the sensitivity, accuracy and negative predictive value of cytopathology for a positive diagnosis of pancreatic cancer. In addition, the presence of KRAS mutations in serum and plasma (liquid biopsies) correlates with a worse prognosis. The presence of mutated KRAS can also have therapeutic implications, whether at the gene level per se, during its post-translational maturation, interaction with nucleotides and after activation of the various oncogenic signals. Further pharmacokinetic and toxicological studies on new molecules are required, especially small synthetic molecules, before they can be used in the therapeutic arsenal for pancreatic ductal adenocarcinoma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Multiple studies have investigated KRAS mutation as a prognostic factor in patients with PDAC (58) and have arriving at mixed findings.”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [58]
Citations
Cites
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809775 · Cited by 2,874
Circulating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K., Goodman, S., Li, M., Thornton, K., Agrawal, N., Sokoll, L., Szabo, S. A., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,734
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Kamerkar, S., LeBleu, V. S., Sugimoto, H., Yang, S., Ruivo, C. F., Melo, S. A., Lee, J. J., & Kalluri, R. (2017) · Nature · doi:10.1038/nature22341 · Cited by 2,639
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Ryan, D. P., Hong, T. S., & Bardeesy, N. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1404198 · Cited by 2,348
Liquid Biopsies: Genotyping Circulating Tumor DNA
Diaz, L. A., & Bardelli, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2011 · Cited by 2,210
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells
Commisso, C., Davidson, S. M., Soydaner-Azeloglu, R. G., Parker, S. J., Kamphorst, J. J., Hackett, S., Grabocka, E., Nofal, M., Drebin, J. A., Thompson, C. B., et al. (2013) · Nature · doi:10.1038/nature12138 · Cited by 1,683
Guerra, C., Schuhmacher, A. J., Cañamero, M., Grippo, P. J., Verdaguer, L., Pérez-Gallego, L., Dubus, P., Sandgren, E. P., & Barbacid, M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.01.012 · Cited by 1,224
Nuclear Acids In Human Blood Plasma.
Mandel, P., & Métais, P. (1948) · PubMed · Cited by 1,196
Therapeutic developments in pancreatic cancer: current and future perspectives
Neoptolemos, J. P., Kleeff, J., Michl, P., Costello, E., Greenhalf, W., & Palmer, D. H. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0005-x · Cited by 1,170
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W.-C., Mansour, J., Mollaee, M., Wagner, K.-U., Koduru, P., Yopp, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7744 · Cited by 1,115
Aguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., Redston, M. S., & DePinho, R. A. (2003) · Genes & Development · doi:10.1101/gad.1158703 · Cited by 1,033
Dynamics of the immune reaction to pancreatic cancer from inception to invasion
Clark, C. E., Hingorani, S. R., Mick, R., Combs, C., Tuveson, D. A., & Vonderheide, R. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0175 · Cited by 990
Lesina, M., Kurkowski, M. U., Ludes, K., Rose-John, S., Treiber, M., Klöppel, G., Yoshimura, A., Reindl, W., Sipos, B., Akira, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.009 · Cited by 862
Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
Hunter, J. C., Manandhar, A., Carrasco, M. A., Gurbani, D., Gondi, S., & Westover, K. D. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0203 · Cited by 786
Van Cutsem, E., van de Velde, H., Karasek, P., Oettle, H., Vervenne, W. L., Szawlowski, A., Schoffski, P., Post, S., Verslype, C., Neumann, H., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.112 · Cited by 786
Microenvironmental regulation of therapeutic response in cancer
Klemm, F., & Joyce, J. A. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.11.006 · Cited by 771
Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
Collins, M. A., Bednar, F., Zhang, Y., Brisset, J.-C., Galbán, S., Galbán, C. J., Rakshit, S., Flannagan, K. S., Adsay, N. V., & Pasca di Magliano, M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59227 · Cited by 770
De Roock, W., Jonker, D. J., Di Nicolantonio, F., Sartore-Bianchi, A., Tu, D., Siena, S., Lamba, S., Arena, S., Frattini, M., Piessevaux, H., et al. (2010) · JAMA · doi:10.1001/jama.2010.1535 · Cited by 748
Huang, L., Holtzinger, A., Jagan, I., BeGora, M., Lohse, I., Ngai, N., Nostro, C., Wang, R., Muthuswamy, L. B., Crawford, H. C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3973 · Cited by 740
Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia
Pylayeva-Gupta, Y., Lee, K. E., Hajdu, C. H., Miller, G., & Bar-Sagi, D. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.024 · Cited by 721
Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
Kapoor, A., Yao, W., Ying, H., Hua, S., Liewen, A., Wang, Q., Zhong, Y., Wu, C.-J., Sadanandam, A., Hu, B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.003 · Cited by 716
EUS-guided FNA for diagnosis of solid pancreatic neoplasms: a meta-analysis
Hewitt, M. J., McPhail, M. J. W., Possamai, L., Dhar, A., Vlavianos, P., & Monahan, K. J. (2012) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2011.08.049 · Cited by 692
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
Bryant, K. L., Stalnecker, C. A., Zeitouni, D., Klomp, J. E., Peng, S., Tikunov, A. P., Gunda, V., Pierobon, M., Waters, A. M., George, S. D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0368-8 · Cited by 692
Bardeesy, N., Cheng, K.-H., Berger, J. H., Chu, G. C., Pahler, J., Olson, P., Hezel, A. F., Horner, J., Lauwers, G. Y., Hanahan, D., et al. (2006) · Genes & Development · doi:10.1101/gad.1478706 · Cited by 674
Kinsey, C. G., Camolotto, S. A., Boespflug, A. M., Guillen, K. P., Foth, M., Truong, A., Schuman, S. S., Shea, J. E., Seipp, M. T., Yap, J. T., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0367-9 · Cited by 634
Targeting protein prenylation for cancer therapy
Berndt, N., Hamilton, A. D., & Sebti, S. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3151 · Cited by 614
Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling
Zimmermann, G., Papke, B., Ismail, S., Vartak, N., Chandra, A., Hoffmann, M., Hahn, S. A., Triola, G., Wittinghofer, A., Bastiaens, P. I. H., et al. (2013) · Nature · doi:10.1038/nature12205 · Cited by 596
Challenges in diagnosis of pancreatic cancer
Zhang, L., Sanagapalli, S., & Stoita, A. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i19.2047 · Cited by 588
Cohen, J. D., Javed, A. A., Thoburn, C., Wong, F., Tie, J., Gibbs, P., Schmidt, C. M., Yip-Schneider, M. T., Allen, P. J., Schattner, M., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704961114 · Cited by 582
Bardeesy, N., Aguirre, A. J., Chu, G. C., Cheng, K.-H., Lopez, L. V., Hezel, A. F., Feng, B., Brennan, C., Weissleder, R., Mahmood, U., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601273103 · Cited by 581
Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features
Puleo, F., Nicolle, R., Blum, Y., Cros, J., Marisa, L., Demetter, P., Quertinmont, E., Svrcek, M., Elarouci, N., Iovanna, J., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.08.033 · Cited by 563
Ihle, N. T., Byers, L. A., Kim, E. S., Saintigny, P., Lee, J. J., Blumenschein, G. R., Tsao, A., Liu, S., Larsen, J. E., Wang, J., et al. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr523 · Cited by 532
EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis
Ardito, C. M., Grüner, B. M., Takeuchi, K. K., Lubeseder-Martellato, C., Teichmann, N., Mazur, P. K., DelGiorno, K. E., Carpenter, E. S., Halbrook, C. J., Hall, J. C., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.07.024 · Cited by 517
Guerra, C., Collado, M., Navas, C., Schuhmacher, A. J., Hernández-Porras, I., Cañamero, M., Rodriguez-Justo, M., Serrano, M., & Barbacid, M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.05.011 · Cited by 516
Allenson, K., Castillo, J., San Lucas, F. A., Scelo, G., Kim, D. U., Bernard, V., Davis, G., Kumar, T., Katz, M., Overman, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx004 · Cited by 493
Taly, V., Pekin, D., Benhaim, L., Kotsopoulos, S. K., Le Corre, D., Li, X., Atochin, I., Link, D. R., Griffiths, A. D., Pallier, K., et al. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.206359 · Cited by 492
Sausen, M., Phallen, J., Adleff, V., Jones, S., Leary, R. J., Barrett, M. T., Anagnostou, V., Parpart-Li, S., Murphy, D., Kay Li, Q., et al. (2015) · Nature Communications · doi:10.1038/ncomms8686 · Cited by 484
Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes
Mueller, S., Engleitner, T., Maresch, R., Zukowska, M., Lange, S., Kaltenbacher, T., Konukiewitz, B., Öllinger, R., Zwiebel, M., Strong, A., et al. (2018) · Nature · doi:10.1038/nature25459 · Cited by 431
Roles for KRAS in Pancreatic Tumor Development and Progression
di Magliano, M. P., & Logsdon, C. D. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.071 · Cited by 400
EGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocarcinoma
Navas, C., Hernández-Porras, I., Schuhmacher, A. J., Sibilia, M., Guerra, C., & Barbacid, M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.001 · Cited by 391
Izeradjene, K., Combs, C., Best, M., Gopinathan, A., Wagner, A., Grady, W. M., Deng, C.-X., Hruban, R. H., Adsay, N. V., Tuveson, D. A., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.01.017 · Cited by 379
An integrin β3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition
Seguin, L., Kato, S., Franovic, A., Camargo, M. F., Lesperance, J., Elliott, K. C., Yebra, M., Mielgo, A., Lowy, A. M., Husain, H., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb2953 · Cited by 374
KRAS Alleles: The Devil Is in the Detail
Haigis, K. M. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.08.006 · Cited by 373
Infante, J. R., Somer, B. G., Park, J. O., Li, C.-P., Scheulen, M. E., Kasubhai, S. M., Oh, D.-Y., Liu, Y., Redhu, S., Steplewski, K., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.024 · Cited by 370
Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation
Tape, C. J., Ling, S., Dimitriadi, M., McMahon, K. M., Worboys, J. D., Leong, H. S., Norrie, I. C., Miller, C. J., Poulogiannis, G., Lauffenburger, D. A., et al. (2016) · Cell · doi:10.1016/j.cell.2016.03.029 · Cited by 369
Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer
Bernard, V., Kim, D. U., San Lucas, F. A., Castillo, J., Allenson, K., Mulu, F. C., Stephens, B. M., Huang, J., Semaan, A., Guerrero, P. A., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.09.022 · Cited by 363
Zhang, W., Nandakumar, N., Shi, Y., Manzano, M., Smith, A., Graham, G., Gupta, S., Vietsch, E. E., Laughlin, S. Z., Wadhwa, M., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2005049 · Cited by 360
Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
Cox, A. D., Der, C. J., & Philips, M. R. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3214 · Cited by 351
Löhr, M., Klöppel, G., Maisonneuve, P., Lowenfels, A. B., & Lüttges, J. (2005) · Neoplasia · doi:10.1593/neo.04445 · Cited by 343
Context-Dependent Transformation of Adult Pancreatic Cells by Oncogenic K-Ras
Friedlander, S. Y. G., Chu, G. C., Snyder, E. L., Girnius, N., Dibelius, G., Crowley, D., Vasile, E., DePinho, R. A., & Jacks, T. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.027 · Cited by 338
Zhang, Y., Velez-Delgado, A., Mathew, E., Li, D., Mendez, F. M., Flannagan, K., Rhim, A. D., Simeone, D. M., Beatty, G. L., & Pasca di Magliano, M. (2017) · Gut · doi:10.1136/gutjnl-2016-312078 · Cited by 337
Golan, T., Khvalevsky, E. Z., Hubert, A., Gabai, R. M., Hen, N., Segal, A., Domb, A., Harari, G., David, E. B., Raskin, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4183 · Cited by 336
Chandra, A., Grecco, H. E., Pisupati, V., Perera, D., Cassidy, L., Skoulidis, F., Ismail, S. A., Hedberg, C., Hanzal-Bayer, M., Venkitaraman, A. R., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2394 · Cited by 325
Therapeutic Targeting of Oncogenic K‐Ras by a Covalent Catalytic Site Inhibitor
Lim, S. M., Westover, K. D., Ficarro, S. B., Harrison, R. A., Choi, H. G., Pacold, M. E., Carrasco, M., Hunter, J., Kim, N. D., Xie, T., et al. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307387 · Cited by 300
Mutant KRAS is a druggable target for pancreatic cancer
Zorde Khvalevsky, E., Gabai, R., Rachmut, I. H., Horwitz, E., Brunschwig, Z., Orbach, A., Shemi, A., Golan, T., Domb, A. J., Yavin, E., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314307110 · Cited by 295
Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker
Pietrasz, D., Pécuchet, N., Garlan, F., Didelot, A., Dubreuil, O., Doat, S., Imbert-Bismut, F., Karoui, M., Vaillant, J.-C., Taly, V., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0806 · Cited by 268
Chiou, S.-H., Winters, I. P., Wang, J., Naranjo, S., Dudgeon, C., Tamburini, F. B., Brady, J. J., Yang, D., Grüner, B. M., Chuang, C.-H., et al. (2015) · Genes & Development · doi:10.1101/gad.264861.115 · Cited by 264
Qian, Z. R., Rubinson, D. A., Nowak, J. A., Morales-Oyarvide, V., Dunne, R. F., Kozak, M. M., Welch, M. W., Brais, L. K., Da Silva, A., Li, T., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3420 · Cited by 260
Small RNA combination therapy for lung cancer
Xue, W., Dahlman, J. E., Tammela, T., Khan, O. F., Sood, S., Dave, A., Cai, W., Chirino, L. M., Yang, G. R., Bronson, R., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412686111 · Cited by 242
Detection of K‐ras gene mutation by liquid biopsy in patients with pancreatic cancer
Kinugasa, H., Nouso, K., Miyahara, K., Morimoto, Y., Dohi, C., Tsutsumi, K., Kato, H., Matsubara, T., Okada, H., & Yamamoto, K. (2015) · Cancer · doi:10.1002/cncr.29364 · Cited by 239
Bodoky, G., Timcheva, C., Spigel, D. R., La Stella, P. J., Ciuleanu, T. E., Pover, G., & Tebbutt, N. C. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9687-4 · Cited by 236
Pancreatic Cancer Metabolism: Breaking It Down to Build It Back Up
Perera, R. M., & Bardeesy, N. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0671 · Cited by 217
Lee, B., Lipton, L., Cohen, J., Tie, J., Javed, A. A., Li, L., Goldstein, D., Burge, M., Cooray, P., Nagrial, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz200 · Cited by 215
Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse
TRACERx Consortium, Chemi, F., Rothwell, D. G., McGranahan, N., Gulati, S., Abbosh, C., Pearce, S. P., Zhou, C., Wilson, G. A., Jamal-Hanjani, M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0593-1 · Cited by 213
KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma
Bournet, B., Muscari, F., Buscail, C., Assenat, E., Barthet, M., Hammel, P., Selves, J., Guimbaud, R., Cordelier, P., & Buscail, L. (2016) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2016.18 · Cited by 205
Self-citationNew biomarkers and targets in pancreatic cancer and their application to treatment
Costello, E., Greenhalf, W., & Neoptolemos, J. P. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.119 · Cited by 195
Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer
Takai, E., Totoki, Y., Nakamura, H., Morizane, C., Nara, S., Hama, N., Suzuki, M., Furukawa, E., Kato, M., Hayashi, H., et al. (2015) · Scientific Reports · doi:10.1038/srep18425 · Cited by 192
KRAS-related proteins in pancreatic cancer
Mann, K. M., Ying, H., Juan, J., Jenkins, N. A., & Copeland, N. G. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.09.003 · Cited by 187
Earl, J., Garcia-Nieto, S., Martinez-Avila, J. C., Montans, J., Sanjuanbenito, A., Rodríguez-Garrote, M., Lisa, E., Mendía, E., Lobo, E., Malats, N., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1779-7 · Cited by 179
Genetically engineered mouse models of pancreatic adenocarcinoma
Guerra, C., & Barbacid, M. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.02.002 · Cited by 179
KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
Zeitouni, D., Pylayeva-Gupta, Y., Der, C., & Bryant, K. (2016) · Cancers · doi:10.3390/cancers8040045 · Cited by 179
Metastatic pancreatic cancer is dependent on oncogenic Kras in mice
Collins, M. A., Brisset, J.-C., Zhang, Y., Bednar, F., Pierre, J., Heist, K. A., Galbán, C. J., Galbán, S., & di Magliano, M. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049707 · Cited by 178
Fleming, J. B., Shen, G.-L., Holloway, S. E., Davis, M., & Brekken, R. A. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-04-0206 · Cited by 176
Trametinib: a MEK inhibitor for management of metastatic melanoma
Rutkowski, P., Lugowska, I., Kosela-Paterczyk, H., & Kozak, K. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s72951 · Cited by 171
Hadano, N., Murakami, Y., Uemura, K., Hashimoto, Y., Kondo, N., Nakagawa, N., Sueda, T., & Hiyama, E. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.175 · Cited by 171
Siveke, J. T., Einwächter, H., Sipos, B., Lubeseder–Martellato, C., Klöppel, G., & Schmid, R. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.002 · Cited by 170
A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations
Riely, G. J., Johnson, M. L., Medina, C., Rizvi, N. A., Miller, V. A., Kris, M. G., Pietanza, M. C., Azzoli, C. G., Krug, L. M., Pao, W. J., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318223c099 · Cited by 168
Maresch, R., Mueller, S., Veltkamp, C., Öllinger, R., Friedrich, M., Heid, I., Steiger, K., Weber, J., Engleitner, T., Barenboim, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms10770 · Cited by 166
Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities
Bournet, B., Buscail, C., Muscari, F., Cordelier, P., & Buscail, L. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.012 · Cited by 164
Self-citationSavides, T. J., Donohue, M., Hunt, G., Al-Haddad, M., Aslanian, H., Ben-Menachem, T., Chen, V. K., Coyle, W., Deutsch, J., DeWitt, J., et al. (2007) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2007.01.017 · Cited by 161
p53 mutations cooperate with oncogenic Kras to promote adenocarcinoma from pancreatic ductal cells
Bailey, J. M., Hendley, A. M., Lafaro, K. J., Pruski, M. A., Jones, N. C., Alsina, J., Younes, M., Maitra, A., McAllister, F., Iacobuzio-Donahue, C. A., et al. (2016) · Oncogene · doi:10.1038/onc.2015.441 · Cited by 154
Clinical Validation of KRAS, BRAF, and EGFR Mutation Detection Using Next-Generation Sequencing
Lin, M.-T., Mosier, S. L., Thiess, M., Beierl, K. F., Debeljak, M., Tseng, L.-H., Chen, G., Yegnasubramanian, S., Ho, H., Cope, L., et al. (2014) · American Journal of Clinical Pathology · doi:10.1309/ajcpmwgwgo34egod · Cited by 153
Kawesha, A., Ghaneh, P., Andrén‐Sandberg, Å., Ögraed, D., Skar, R., Dawiskiba, S., Evans, J. D., Campbell, F., Lemoine, N. R., & Neoptolemos, J. P. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001120)89:6<506::aid-ijc7>3.0.co;2-f · Cited by 152
Yoshinaga, S., Suzuki, H., Oda, I., & Saito, Y. (2011) · Digestive Endoscopy · doi:10.1111/j.1443-1661.2011.01112.x · Cited by 150
Chronic pancreatitis: A path to pancreatic cancer
Pinho, A. V., Chantrill, L. A., & Rooman, I. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.08.015 · Cited by 150
Molecular subtypes in cancers of the gastrointestinal tract
Bijlsma, M. F., Sadanandam, A., Tan, P. B. O., & Vermeulen, L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.33 · Cited by 150
Kawesha, A., Ghaneh, P., Andrén-Sandberg, Å., Ögraed, D., Skar, R., Dawiskiba, S., Evans, J. D., Campbell, F., Lemoine, N., & Neoptolemos, J. P. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001120)89:6<469::aid-ijc1>3.0.co;2-l · Cited by 149
Critical role of NF-κB in pancreatic cancer
Prabhu, L., Mundade, R., Korc, M., Loehrer, P. J., & Lu, T. (2014) · Oncotarget · doi:10.18632/oncotarget.2624 · Cited by 148
Cheng, H., Liu, C., Jiang, J., Luo, G., Lu, Y., Jin, K., Guo, M., Zhang, Z., Xu, J., Liu, L., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30650 · Cited by 145
Kim, S. T., Lim, D. H., Jang, K.-T., Lim, T., Lee, J., Choi, Y.-L., Jang, H.-L., Yi, J. H., Baek, K. K., Park, S. H., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0269 · Cited by 145
Circulating DNA as a Possible Factor in Oncogenesis
Bendich, A., Wilczok, T., & Borenfreund, E. (1965) · Science · doi:10.1126/science.148.3668.374 · Cited by 144
Cell of origin affects tumour development and phenotype in pancreatic ductal adenocarcinoma
Lee, A. Y. L., Dubois, C. L., Sarai, K., Zarei, S., Schaeffer, D. F., Sander, M., & Kopp, J. L. (2019) · Gut · doi:10.1136/gutjnl-2017-314426 · Cited by 139
Collins, M. A., Yan, W., Sebolt–Leopold, J. S., & Pasca di Magliano, M. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.11.052 · Cited by 133
Toubaji, A., Achtar, M. S., Provenzano, M., Herrin, V. E., Behrens, R. J., Hamilton, M., Bernstein, S. A., Venzon, D. J., Gause, B. L., Marincola, F. M., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0477-6 · Cited by 129
Differential diagnosis of pancreatic cancer and focal pancreatitis by using EUS-guided FNA
Takahashi, K., Yamao, K., Okubo, K., Sawaki, A., Mizuno, N., Ashida, R., Koshikawa, T., Ueyama, Y., Kasugai, K., Hase, S., et al. (2005) · Gastrointestinal Endoscopy · doi:10.1016/s0016-5107(04)02224-2 · Cited by 129
K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer
Chen, H., Tu, H., Meng, Z. Q., Chen, Z., Wang, P., & Liu, L. M. (2010) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2010.05.014 · Cited by 128
Lee, J., Jang, K., Ki, C., Lim, T., Park, Y. S., Lim, H. Y., Choi, D., Kang, W. K., Park, K., & Park, J. O. (2007) · Cancer · doi:10.1002/cncr.22559 · Cited by 127
Genetic and Epigenetic Alterations in Pancreatic Carcinogenesis
Delpu, Y., Hanoun, N., Lulka, H., Sicard, F., Selves, J., Buscail, L., Torrisani, J., & Cordelier, P. (2011) · Current Genomics · doi:10.2174/138920211794520132 · Cited by 123
Self-citationApplication of COLD-PCR for improved detection of KRAS mutations in clinical samples
Zuo, Z., Chen, S. S., Chandra, P., Galbincea, J. M., Soape, M. P., Doan, S., Barkoh, B. A., Koeppen, H., Medeiros, L. J., & Luthra, R. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.59 · Cited by 123
Ogura, T., Yamao, K., Hara, K., Mizuno, N., Hijioka, S., Imaoka, H., Sawaki, A., Niwa, Y., Tajika, M., Kondo, S., et al. (2012) · Journal of Gastroenterology · doi:10.1007/s00535-012-0664-2 · Cited by 118
Fuccio, L., Hassan, C., Laterza, L., Correale, L., Pagano, N., Bocus, P., Fabbri, C., Maimone, A., Cennamo, V., Repici, A., et al. (2013) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2013.04.162 · Cited by 117
Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer
Sinicrope, F. A., Okamoto, K., Kasi, P. M., & Kawakami, H. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.02.008 · Cited by 116
Development of siRNA Payloads to Target KRAS -Mutant Cancer
Yuan, T. L., Fellmann, C., Lee, C.-S., Ritchie, C. D., Thapar, V., Lee, L. C., Hsu, D. J., Grace, D., Carver, J. O., Zuber, J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0900 · Cited by 113
Impact of delay between imaging and treatment in patients with potentially curable pancreatic cancer
Sanjeevi, S., Ivanics, T., Lundell, L. R., Kartalis, N., Andrén‐Sandberg, Å., Blomberg, J., Chiaro, M. D., & Ansorge, C. (2015) · British journal of surgery · doi:10.1002/bjs.10046 · Cited by 108
Brychta, N., Krahn, T., & von Ahsen, O. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2016.257469 · Cited by 108
Shin, S. H., Kim, S. C., Hong, S.-M., Kim, Y. H., Song, K.-B., Park, K.-M., & Lee, Y.-J. (2013) · Pancreas · doi:10.1097/mpa.0b013e31825b6ab0 · Cited by 107
Wei, T., Zhang, Q., Li, X., Su, W., Li, G., Ma, T., Gao, S., Lou, J., Que, R., Zheng, L., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1298 · Cited by 105
Laheru, D., Shah, P., Rajeshkumar, N. V., McAllister, F., Taylor, G., Goldsweig, H., Le, D. T., Donehower, R., Jimeno, A., Linden, S., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9818-6 · Cited by 104
Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer
Van Cutsem, E., Hidalgo, M., Canon, J., Macarulla, T., Bazin, I., Poddubskaya, E., Manojlovic, N., Radenkovic, D., Verslype, C., Raymond, E., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31603 · Cited by 104
Focus on an unusual rise in pancreatic cancer incidence in France
Bouvier, A., Uhry, Z., Jooste, V., Drouillard, A., Remontet, L., Launoy, G. D., Léone, N., & the French Network of Cancer Registries (FRANCIM) (2017) · International Journal of Epidemiology · doi:10.1093/ije/dyx088 · Cited by 104
Biomarkers in pancreatic adenocarcinoma: current perspectives
Swords, D. S., Firpo, M. A., Scaife, C. L., & Mulvihill, S. J. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s100510 · Cited by 102
Dong, L., Wang, S., Fu, B., & Wang, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-27368-3 · Cited by 101
Salek, C. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i27.3714 · Cited by 99
Singh, N., Gupta, S., Pandey, R. M., Chauhan, S. S., & Saraya, A. (2015) · Cancer Investigation · doi:10.3109/07357907.2014.1001894 · Cited by 98
Kim, M. K., Woo, S. M., Park, B., Yoon, K., Kim, Y., Joo, J., Lee, W. J., Han, S., Park, S., & Kong, S. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2017.283721 · Cited by 96
Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs
Pecot, C. V., Wu, S. Y., Bellister, S., Filant, J., Rupaimoole, R., Hisamatsu, T., Bhattacharya, R., Maharaj, A., Azam, S., Rodriguez-Aguayo, C., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0074 · Cited by 95
Somatic Mutations in Exocrine Pancreatic Tumors: Association with Patient Survival
Rachakonda, P. S., Bauer, A. S., Xie, H., Campa, D., Rizzato, C., Canzian, F., Beghelli, S., Greenhalf, W., Costello, E., Schanne, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060870 · Cited by 93
Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer
Riva, F., Dronov, O. I., Khomenko, D. I., Huguet, F., Louvet, C., Mariani, P., Stern, M.-H., Lantz, O., Proudhon, C., Pierga, J.-Y., et al. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.01.006 · Cited by 93
Bournet, B., Souque, A., Senesse, P., Assenat, E., Barthet, M., Lesavre, N., Aubert, A., O'Toole, D., Hammel, P., Levy, P., et al. (2009) · Endoscopy · doi:10.1055/s-0029-1214717 · Cited by 91
Self-citationMatsuo, Y., Campbell, P. M., Brekken, R. A., Sung, B., Ouellette, M. M., Fleming, J. B., Aggarwal, B. B., Der, C. J., & Guha, S. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0577 · Cited by 91
Implication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter?
Baer, R., Cintas, C., Therville, N., & Guillermet‐Guibert, J. (2015) · Advances in Biological Regulation · doi:10.1016/j.jbior.2015.05.001 · Cited by 90
Pantsar, T., Rissanen, S., Dauch, D., Laitinen, T., Vattulainen, I., & Poso, A. (2018) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1006458 · Cited by 85
Clinical impact of K-ras mutation analysis in EUS-guided FNA specimens from pancreatic masses
Ogura, T., Yamao, K., Sawaki, A., Mizuno, N., Hara, K., Hijioka, S., Niwa, Y., Tajika, M., Kondo, S., Shimizu, Y., et al. (2012) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2011.11.012 · Cited by 82
Jonckheere, N., Vasseur, R., & SEUNINGEN, I. V. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.002 · Cited by 82
Martin, N. E., Brunner, T. B., Kiel, K. D., DeLaney, T. F., Regine, W. F., Mohiuddin, M., Rosato, E. F., Haller, D. G., Stevenson, J. P., Smith, D., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0248 · Cited by 81
Organoid models for translational pancreatic cancer research
Tiriac, H., Plenker, D., Baker, L. A., & Tuveson, D. A. (2019) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2019.02.003 · Cited by 79
Imamura, T., Komatsu, S., Ichikawa, D., Kawaguchi, T., Miyamae, M., Okajima, W., Ohashi, T., Arita, T., Konishi, H., Shiozaki, A., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i25.5627 · Cited by 78
Boeck, S., Jung, A., Laubender, R. P., Neumann, J., Egg, R., Goritschan, C., Ormanns, S., Haas, M., Modest, D. P., Kirchner, T., et al. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0767-4 · Cited by 77
RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally
Miller, M. S., & Miller, L. D. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2011.00100 · Cited by 76
ERK1/2 activity contributes to gemcitabine resistance in pancreatic cancer cells
Zheng, C., Jiao, X., Jiang, Y., & Sun, S. (2013) · Journal of International Medical Research · doi:10.1177/0300060512474128 · Cited by 74
Liquid Biopsy Approach for Pancreatic Ductal Adenocarcinoma
Buscail, E., Maulat, C., Muscari, F., Chiche, L., Cordelier, P., Dabernat, S., Alix-Panabières, C., & Buscail, L. (2019) · Cancers · doi:10.3390/cancers11060852 · Cited by 74
Self-citationTreatment of Advanced Pancreatic Cancer
Ducreux, M. P., Boige, V., & Malka, D. (2007) · Seminars in Oncology · doi:10.1053/j.seminoncol.2007.01.006 · Cited by 73
Schultz, N. A., Roslind, A., Christensen, I. J., Horn, T., Høgdall, E., Pedersen, L. N., Kruhøffer, M., Burcharth, F., Wøjdemann, M., & Johansen, J. S. (2012) · Pancreas · doi:10.1097/mpa.0b013e31823cd9df · Cited by 68
Mosolits, S., Ullenhag, G. J., & Mellstedt, H. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi192 · Cited by 67
Recent advances in cancer drug discovery targeting RAS
Wilson, C., & Tolias, P. P. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.08.002 · Cited by 66
Nanofluidic Digital PCR for KRAS Mutation Detection and Quantification in Gastrointestinal Cancer
Azuara, D., Morell, M., Gausachs, M., Rodríguez‐Moranta, F., Fabregat, J., Busquets, J., Peláez, N., Boadas, J., Galter, S., Moreno, V. R., et al. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2012.186577 · Cited by 65
Däbritz, J., Preston, R., Hänfler, J., & Oettle, H. (2009) · Pancreas · doi:10.1097/mpa.0b013e31819f6376 · Cited by 64
Maluf‐Filho, F., Kumar, A., Gerhardt, R., Kubrusly, M. S., Sakai, P., Hondo, F. Y., MATUGUMA, S. E., Artifon, E. L. A., da Cunha, J. E. M., Machado, M. C. C., et al. (2007) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31805905e9 · Cited by 63
Laethem, J. V., Riess, H. B., Jassem, J., Haas, M., Martens, U. M., Weekes, C. D., Peeters, M., Ross, P. J., Bridgewater, J. A., Melichar, B., et al. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0469-y · Cited by 63
Are, C., Chowdhury, S., Ahmad, H. F., Ravipati, A., Song, T., Shrikandhe, S., & Smith, L. M. (2016) · Journal of Surgical Oncology · doi:10.1002/jso.24410 · Cited by 63 · cited 1×
“motif of KRAS site of farnesylation (CAAX) (reticulum and Golgi apparatus) (tipifarnib, lonafarnib) (2).”
BackgroundKRAS Testing: A Tool for the Implementation of Personalized Medicine
Shackelford, R. E., Whitling, N. A., McNab, P. M., Japa, S., & Coppola, D. (2012) · Genes & Cancer · doi:10.1177/1947601912460547 · Cited by 61
Asati, V., Mahapatra, D. K., & Bharti, S. K. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.049 · Cited by 61
Pellisé, M., Castells, A., Ginés, À., Solé, M., Móra, J., Castellví-Bel, S., Rodríguez‐Moranta, F., Fernández‐Esparrach, G., Llach, J., Bordas, J. M., et al. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01579.x · Cited by 61
Bournet, B., Selves, J., Grand, D., Danjoux, M., Hanoun, N., Cordelier, P., & Buscail, L. (2015) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000053 · Cited by 61
Self-citationFactors Affecting the Development of Diabetes Mellitus After Pancreatic Resection
Kwon, J. H., Kim, S. C., Shim, I. K., Song, K. B., Lee, J. H., Hwang, D. W., Park, K., & Lee, Y. J. (2015) · Pancreas · doi:10.1097/mpa.0000000000000404 · Cited by 60
Interventional Endoscopic Ultrasound in Pancreatic Diseases
Buscail, L., Fauré, P., Bournet, B., Sèlves, J., & Escourrou, J. R. (2005) · Pancreatology · doi:10.1159/000090022 · Cited by 60
Self-citationLaboratory methods forKRASmutation analysis
Anderson, S. M. (2011) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.11.42 · Cited by 59
Park, G., Park, J. K., Son, D., Shin, S., Kim, Y. J., Jeon, H.-J., Lee, J., Park, W., Lee, K. H., & Park, D. (2018) · Scientific Reports · doi:10.1038/s41598-018-30100-w · Cited by 59
Linardou, H., Briasoulis, E. C., Dahabreh, I. J., Mountzios, G., PAPADIMITRIOU, C. A., Papadopoulos, S., Bafaloukos, D. I., Kosmidis, P., & Murray, S. J. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.07.008 · Cited by 56
Oh, J. E., Lim, H. S., An, C. H., Jeong, E. G., Han, J. Y., Lee, S. H., & Yoo, N. J. (2010) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2010.090146 · Cited by 55
MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer.
Gayral, M., Jo, S., Hanoun, N., Vignolle-Vidoni, A., Lulka, H., Delpu, Y., Meulle, A., Dufresne, M., Humeau, M., du Rieu, M. C., et al. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i32.11199 · Cited by 54
A comparability study of 5 commercial KRAS tests
Oliner, K., Juan, T., Suggs, S., Wolf, M., Sarosi, I., Freeman, D. J., Gyuris, T., Baron, W., Bakker, A., Parker, A., et al. (2010) · Diagnostic Pathology · doi:10.1186/1746-1596-5-23 · Cited by 52
Niedergethmann, M., Rexin, M., Hildenbrand, R., Knob, S., Sturm, J. W., Richter, A., & Post, S. (2002) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200212000-00005 · Cited by 52
Oliveira-Cunha, M., Hadfield, K. D., Siriwardena, A. K., & Newman, W. (2012) · Pancreas · doi:10.1097/mpa.0b013e3182327a03 · Cited by 51
KRAS: Reasons for optimism in lung cancer
Lindsay, C. R., Jamal-Hanjani, M., Forster, M., & Blackhall, F. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.05.001 · Cited by 51
Kit, A. H., Mazaleyrat, N., Daunay, A., Nielsen, H. M., Terris, B., & Tost, J. (2013) · Human Mutation · doi:10.1002/humu.22427 · Cited by 50
Sarasqueta, A. F., Moerland, E., de Bruyne, H., de Graaf, H., Vrancken, T., van Lijnschoten, G., & van den Brule, A. J. C. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2010.10.006 · Cited by 48
Ogura, T., Yamao, K., Sawaki, A., Mizuno, N., Hara, K., Hijioka, S., Niwa, Y., Tajika, M., Kondo, S., Shimizu, Y., et al. (2012) · Gastrointestinal Endoscopy · Cited by 48
MEK inhibitors in oncology: a patent review (2015-Present)
Mahapatra, D. K., Asati, V., & Bharti, S. K. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1339688 · Cited by 47
Zhang, R., Peng, R., Li, Z., Gao, P., Jia, S., Yang, X., Ding, J., Han, Y., Xie, J., & Li, J. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2017.272559 · Cited by 47
Buscail, É., Chiche, L., Laurent, C., Vendrely, V., Denost, Q., Denis, J. A., Thumerel, M., Lacorte, J., Bedel, A., Moreau‐Gaudry, F., et al. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12534 · Cited by 47
Andriamanampisoa, C.-L., Bancaud, A., Rodat, A., Didelot, A., Fabre, J., Fina, F., Garlan, F., Garrigou, S., Gaudy‐Marqueste, C., Ginot, F., et al. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.7b04034 · Cited by 45
Quandt, J., Schlude, C., Bartoschek, M., Will, R. D., Arregui, A. C., Schölch, S., Reißfelder, C., Weitz, J., Schneider, M. A., Wiemann, S., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1500671 · Cited by 45
Analytical Validation of Genotyping Assays in the Biomarker Laboratory
Isler, J. A., Vesterqvist, O., & Burczynski, M. E. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.4.353 · Cited by 45
Morgan, R. J., Leong, L., Chow, W., Gandara, D., Frankel, P., Garcia, A., Lenz, H.-J., & Doroshow, J. H. (2012) · Investigational New Drugs · doi:10.1007/s10637-010-9557-5 · Cited by 44
Reicher, S., Boyar, F. Z., Albitar, M. X., Sulcova, V., Agersborg, S. S., Nga, V., Zhou, Y., Li, G., Venegas, R. J., French, S. W., et al. (2011) · Pancreas · doi:10.1097/mpa.0b013e3182200201 · Cited by 44
Kamata, K., Takenaka, M., Omoto, S., Miyata, T., Minaga, K., Yamao, K., Imai, H., Sakurai, T., Nishida, N., Chikugo, T., et al. (2017) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2017.05.052 · Cited by 44
Sinn, B. V., Striefler, J. K., Rudl, M. A., Lehmann, A., Bahra, M., Denkert, C., Sinn, M., Stieler, J., Klauschen, F., Budczies, J., et al. (2014) · Pancreas · doi:10.1097/mpa.0000000000000077 · Cited by 43
S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma
Bachet, J., Maréchal, R., Demetter, P., Bonnetain, F., Cros, J. F., Svrcek, M., Bardier–Dupas, A., Hammel, P. R., Sauvanet, A., Louvet, C., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.04.017 · Cited by 42
Transcriptional regulation of the interleukin-11 gene by oncogenic Ras
Shin, S. Y., Choi, C., Lee, H. G., Lim, Y. C., & Lee, Y. H. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs297 · Cited by 41
Cohn, A., Morse, M. A., O’Neil, B., Whiting, S., Coeshott, C., Ferraro, J., Bellgrau, D., Apelian, D., & Rodell, T. C. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000219 · Cited by 41
Trisolini, E., Armellini, E., Paganotti, A., Veggiani, C., Bozzola, C., Frattini, M., Pizio, C., Mancuso, G., Andorno, S., & Boldorini, R. L. (2017) · Pathology · doi:10.1016/j.pathol.2016.12.348 · Cited by 38
EUS-FNA Mutational Analysis in Differentiating Autoimmune Pancreatitis and Pancreatic Cancer
Khalid, A., DeWitt, J. M., Ohori, N. P., Chen, J.-H., Fasanella, K. E., Sanders, M. K., McGrath, K. M., & Nikiforova, M. N. (2011) · Pancreatology · doi:10.1159/000331505 · Cited by 37
Digital PCR Improves Mutation Analysis in Pancreas Fine Needle Aspiration Biopsy Specimens
Sho, S., Court, C. M., Kim, S. H., Braxton, D. R., Hou, S., Muthusamy, V. R., Watson, R. R., Sedarat, A., Tseng, H., & Tomlinson, J. S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170897 · Cited by 34
Ning, C., Liang, M., Liu, S., Wang, G., Edwards, H. J., Xia, Y., Polin, L., Dyson, G. E., Taub, J. W., Mohammad, R. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17869 · Cited by 33
761 Detection of K-RAS Gene Mutation by Liquid Biopsy in Patients With Pancreatic Cancer
Kinugasa, H., Nouso, K., Miyahara, K., Morimoto, Y., Dohi, C., Tsutsumi, K., Kato, H., Okada, H., & Yamamoto, K. (2015) · Gastroenterology · doi:10.1016/s0016-5085(15)30496-0 · Cited by 33
Lin, M., Alnaggar, M., Liang, S., Chen, J., Xu, K., Dong, S., Du, D., & Niu, L. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000490874 · Cited by 32
Matera, R. M., & Saif, M. W. (2017) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1362388 · Cited by 30
Sekita‐Hatakeyama, Y., Nishikawa, T., Takeuchi, M., Morita, K., Takeda, M., Hatakeyama, K., Nakai, T., Uchiyama, T., Itami, H., Fujii, T., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193692 · Cited by 30
Pritchard, C. C., Akagi, L., Reddy, P. L., Joseph, L. J., & Tait, J. F. (2010) · BMC Clinical Pathology · doi:10.1186/1472-6890-10-6 · Cited by 30
Loss of Heterozygosity Predicts Poor Survival After Resection of Pancreatic Adenocarcinoma
Franko, J., Krasinskas, A. M., Nikiforova, M. N., Zărnescu, N. O., Lee, K. K. W., Hughes, S. J., Bartlett, D. L., Zeh, H. J., & Moser, A. J. (2008) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-008-0577-9 · Cited by 29
Variant Profiling of Candidate Genes in Pancreatic Ductal Adenocarcinoma
Huang, J., Löhr, M. J., NILSSON, M. H. L., Segersvärd, R., Matsson, H., Verbeke, C. S., Heuchel, R. L., Kere, J., Iafrate, A. J., Zheng, Z., et al. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2015.238543 · Cited by 28
Kwon, M. J., Jeon, J. Y., Park, H., Nam, E. S., Cho, S. J., Shin, H. S., Kwon, J. H., Kim, J. S., Han, B., Kim, D. H., et al. (2014) · Pancreas · doi:10.1097/mpa.0000000000000280 · Cited by 22
What’s new in the diagnosis of pancreatic cancer: a patent review (2011-present)
Boulaiz, H., Ramos, M. C., Griñán‐Lisón, C., García-Rubiño, M. E., Vicente, F., & Marchal, J. A. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1379991 · Cited by 22
Pancreatic cancer, treatment options, and GI-4000
Hartley, M. L., Bade, N. A., Prins, P., Ampie, L., & Marshall, J. L. (2014) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2014.1004017 · Cited by 21
Genetic and epigenetic markers in the evaluation of pancreatic masses
Morell, M., Móra, J., Mayor, R., Farré, A., Peinado, M. A., Busquets, J., Serrano, T., Capellá, G., & Fabregat, J. (2012) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201123 · Cited by 18
Pancreatic cancer, treatment options, and GI-4000
Hartley, M. L., Bade, N. A., Prins, P., Ampie, L., & Marshall, J. L. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1011017 · Cited by 17
Water Distribution within Wild-Type NRas Protein and Q61 Mutants during Unrestrained QM/MM Dynamics
Tichauer, R. H., Favre, G., Cabantous, S., Landa, G., Hémeryck, A., & Brut, M. (2018) · Biophysical Journal · doi:10.1016/j.bpj.2018.07.042 · Cited by 16
Cacheux, J., Brut, M., Bancaud, A., Cordelier, P., & Leïchlé, T. (2018) · ACS Sensors · doi:10.1021/acssensors.7b00667 · Cited by 15
Self-citationSmith, M. L. (2010) · Yearbook of Pathology and Laboratory Medicine · doi:10.1016/s1077-9108(09)79315-6 · Cited by 14
STAT3 Inhibition Induces Apoptosis in Cancer Cells Independent of STAT1 or STAT2.
Shodeinde, A., Ginjupalli, K., Lewis, H. D., Riaz, S., & Barton, B. E. (2013) · PubMed · Cited by 13
Abstract 1916: β3 integrin/KRAS/RalB complex drives tumor stemness and resistance to EGFR inhibition
Seguin, L., Kato, S., Franovic, A., Camargo, M. F., Elliott, K., Yebra, M., Lesperance, J., Mielgo, A., Desgrosellier, J. S., Anand, S., et al. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-1916 · Cited by 10
Role of K-ras Mutation Analysis in EUS-FNA Samples Obtained From Pancreatic Solid Mass
Matsubayashi, H. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000192 · Cited by 6
Research works printed but not linked: 1
- Mandel, P. & Metais, P. Les acides nucleiques du plasma sanguin chez l’homme [French]. C. R. Seances Soc. Biol. Fil. 142, 241–243 (1948).
Cited by
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Pancreatic cancer: A review of epidemiology, trend, and risk factors
Hu, J.-X., Zhao, C.-F., Chen, W.-B., Liu, Q.-C., Li, Q.-W., Lin, Y.-Y., & Gao, F. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i27.4298 · Cited by 588
Stoop, T. F., Javed, A. A., Oba, A., Koerkamp, B. G., Seufferlein, T., Wilmink, J. W., & Besselink, M. G. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00261-2 · Cited by 479
Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis
Cai, J., Chen, H., Lu, M., Zhang, Y., Lu, B., You, L., Zhang, T., Dai, M., & Zhao, Y. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.06.027 · Cited by 470
Menyhárt, O., & Győrffy, B. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.01.009 · Cited by 380
Metadata
- Authors
- Buscail, L., Bournet, B., & Cordelier, P.
- Affiliations
- Université Toulouse III - Paul Sabatier (FR)
- Corresponding author
- Buscail, Louis
- Venue
- Nature Reviews Gastroenterology & Hepatology
- Published
- 2020-01-31
- Volume
- 17
- Issue
- 3
- Pages
- 153-168
- ISSN
- 1759-5045 (ISSN-L)
- 1759-5053
- OpenAlex
- W3003574401
- Cited by
- 721
- References
- 202
- Citations by year
- 2026: 70 · 2025: 103 · 2024: 134 · 2023: 121 · 2022: 153 · 2021: 106 · 2020: 34
- FWCI
- 11.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Gastroenterology & Hepatology (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- KRAS mutation, pancreatic ductal adenocarcinoma, pancreatic cancer diagnosis, prognosis, liquid biopsy, KRAS mutation testing, fine-needle aspiration, cytopathology, serum biomarkers, KRAS-targeted therapy
- MeSH terms
- Animals, Disease Models, Animal, Humans, Mice, Transgenic, Mutation, Pancreatic Neoplasms, Prognosis, Biomarkers, Tumor, Signal Transduction, Proto-Oncogene Proteins p21(ras), Carcinoma, Pancreatic Ductal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.